乳がんの生存者に対するホルモン療法の検討
1Cleveland Clinic, Cleveland, Ohio.
まとめ
乳がんの生存者におけるホルモン療法の使用は複雑である. 長期データがないため,安全性や生活の質に関する不確実性が患者や医師に生じます.
科学分野:
- 腫瘍学
- 内分泌学
背景:
- 乳がんの生存者に対するホルモン療法の使用は議論の余地があります.
- 歴史的ガイドラインは,その使用に対して注意を喚起しています.
- 安全性は多因性であるが,長期的な腫瘍学的データは限られている.
研究 の 目的:
- 乳がんの生存者のホルモン療法に関する複雑さと論争を解決するためです
- 決定的な長期的な腫瘍学的データがないことを強調します.
- 不確実な状況下での 臨床的意思決定を促すため
主な方法:
- 乳がんの生存者に対するホルモン療法に関する既存の文献とガイドラインのレビュー.
- 限られた長期腫瘍学データによる影響の分析
- 生活の質と健康に関する議論
主要な成果:
- 乳がんの生存者におけるホルモン療法に関する長期的な腫瘍学的データは不十分です.
- 現在の証拠は安全性に関する決定的な答えを提供していません.
- 患者と医療従事者の両方に 不確実性が残っています
結論:
- ホルモン療法に関する決定は,利用可能な最良の不完全な証拠に基づいて行われなければならない.
- 長期的な安全性と有効性を確立するには,さらなる研究が必要です.
- 患者の生活の質への配慮は最優先です
関連する概念動画
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Cancer Therapies
7.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Tumor Immunotherapy
659
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
659
Target Cell Response to Hormones
3.5K
Hormones intricately bind to receptors on the surface or within target cells, initiating a cascade of cellular responses.
Notably, the cellular response can be regulated by altering the number of receptors expressed in the cell. For example, prolonged exposure to elevated hormone levels results in a gradual decline or down-regulation in the number of receptors for that specific hormone on the cell surface. Conversely, in response to low hormone levels, cells may use up-regulation, producing an...
Notably, the cellular response can be regulated by altering the number of receptors expressed in the cell. For example, prolonged exposure to elevated hormone levels results in a gradual decline or down-regulation in the number of receptors for that specific hormone on the cell surface. Conversely, in response to low hormone levels, cells may use up-regulation, producing an...
3.5K
Hormonal Control of the Ovarian Cycle
2.7K
The ovarian cycle is meticulously regulated by the hypothalamic-pituitary-gonadal axis. This cycle orchestrates the release of a mature oocyte, essential for reproduction.
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...
2.7K


